Investment
Features
FeesSafety
Academy
More
Pluang+

Compare Appian Corp (APPN) vs Cigna Corp (CI) Price & Performance

Appian CorpTrade
Cigna CorpTrade

Price performance (Past 24H)

Key statistics

Appian Corp vs Cigna Corp — how do they compare? Appian Corp trades at $25.94 (market cap $1.86B), while Cigna Corp trades at $302.13 (market cap $77.63B). The key difference: Cigna Corp is far larger — about 41.7× Appian Corp's market cap, and Cigna Corp pays a 2.13% dividend while Appian Corp pays none. Which is the better fit depends on your goals.

APPNCI
Market Cap
$1.86B$77.63B
Sector
TechnologyHealth
52-Week High
$45.64$311.00
52-Week Low
$18.72$244.41
Enterprise Value
$1.95B$100.73B
Dividend Yield
2.13%

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

Appian Corp

Appian (APPN) trades at $25.36, up 0.48% on the day, with a bullish technical signal from moving averages and a consensus price target of $26.20. The company reported positive net income in 2025 after years of losses, with revenue growing to $726.94M and operating cash flow improving to $62.87M. Recent news highlights focus on AI strategy and enterprise adoption, though the CEO's share sale and negative shareholder equity present mixed signals.

The outlook is cautiously optimistic with revenue growth and cash flow recovery, but risks include high debt levels, negative equity, and intense competition. Analyst sentiment is mixed with a majority Hold rating. The stock offers potential from AI-driven growth but requires monitoring of profitability sustainability and balance sheet health.

Cigna Corp

Cigna (CI) trades at $293.46, up 0.57% on the day, with a bullish technical signal and strong analyst support. The stock shows consistent earnings beats, with Q1 2026 EPS of $7.79 exceeding the $7.60 estimate. Valuation metrics appear attractive with a P/E of 12.44 and P/S of 0.28. Recent news highlights strategic initiatives, including AI integration in pharmacy services. The current price is near the consensus price target of $339.82, indicating potential upside.

The outlook for CI is positive, driven by earnings momentum, a favorable analyst consensus, and strategic growth investments. Key risks include regulatory challenges, as seen in a recent lawsuit in Tennessee, and competitive pressures in the healthcare sector. Net cash flow turned negative in 2025, which warrants monitoring. The stock presents a value opportunity with a solid dividend, but investors should weigh execution risks against growth potential.

Returns comparison

Trailing returns across standard periods

Top news

Latest headlines on both assets

About Appian Corp

Appian Corp provides a low-code software development platform as a service that enables organizations to rapidly develop powerful and unique applications. With its platform, organizations can rapidly and easily design, build and implement powerful, enterprise-grade custom applications through intuitive, visual interface with little or no coding required. The company's customers use applications built on its low-code platform to launch new business lines, automate vital employee workflows, manage complex trading platforms, accelerate drug development and build procurement systems. The group generates a majority of its revenue from the domestic market. It serves various industries such as education.

Read more on APPN

About Cigna Corp

Cigna primarily provides pharmacy benefit management and health insurance services. Its PBM services were greatly expanded by its 2018 merger with Express Scripts and are mostly sold to health insurance plans and employers. Its largest PBM contract is the Department of Defense. In health insurance and other benefits, Cigna mostly serves employers through self-funding arrangements, but it also operates in government programs, such as Medicare Advantage. The company operates mostly in the U.S. with 15 million medical members covered as of the end of 2020, but its services extend internationally, covering another 2 million people.

Read more on CI